With a new phase 3 win for Erleada (apalutamide), Johnson & Johnson is proposing a solution to a longstanding prostate cancer treatment gap. | In its 2,000-patient Proteus study, J&J tested Erleada's benefits when given to certain patients with prostate cancer before and after surgery.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
J&J's Erleada study succeeds in early-stage prostate cancer, but questions remain
Prostate cancer breakthrough as drug combo gives patients a powerful new chance
ASCO: Revolution Medicines confident in RAS leadership as rivals square up
Johnson & Johnson prostate cancer drug reduces risk of cancer spread and death in late-stage study
‘Thrilling’: Regimen reduces metastasis, recurrence in high-risk prostate cancer
FDA oncology roundup: AbbVie’s rare cancer approval, AstraZeneca in breast cancer limbo - Pharmaceutical Technology
FDA delays ruling on AstraZeneca’s breast cancer drug after negative adcomm vote
A turning point for pancreatic cancer patients
Convergent Therapeutics Announces Positive Phase 2 Data at ASCO 2026 Showing Promising Anti-Tumor Activity, Durability, and Favorable Tolerability for CONV01-α in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Pfizer appears to have one-upped Johnson & Johnson again in their PARP inhibitor battle in prostate cancer. | After winning a…
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces…
Editor's Note: The story will be updated after the study's presentation Friday afternoon. Please check back later. | About three…
As part of a hormone therapy regimen for prostate cancer, J&J’s Erleada cut the risk of metastasis or death by 20% when given…
Data from a late-stage trial, presented on Sunday, indicate that the treatment, administered six months before and after surgery,…
UNDER EMBARGO: Sunday May 31 7AM CST/ 8AM EST | In Lilly's Libretto-432 ASCO readout, Retevmo showed an 83% reduction in disease…
